Loading
Latest filing published 05 Jun 2026 for Assembly Biosciences, INC..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Jason A. Okazaki in Assembly Biosciences, Inc., where the filings describe the role as senior executive. Between 26 March 2020 and 29 March 2026, the trades on record add up to 24 filings.
Sales make up the whole of the open-market record (14 sales, €93k). The rest of the record consists of 10 share grants.
On 5 June 2026 came the latest disclosure, a share grant in Assembly Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations